Nutriband Inc. (NTRB)
NASDAQ: NTRB · Real-Time Price · USD
4.810
-0.130 (-2.63%)
Nov 22, 2024, 4:00 PM EST - Market closed
Nutriband Revenue
Nutriband had revenue of $442.83K in the quarter ending July 31, 2024, a decrease of -32.49%. This brings the company's revenue in the last twelve months to $1.80M, down -20.83% year-over-year. In the fiscal year ending January 31, 2024, Nutriband had annual revenue of $2.09M with 0.27% growth.
Revenue (ttm)
$1.80M
Revenue Growth
-20.83%
P/S Ratio
24.25
Revenue / Employee
$138,755
Employees
13
Market Cap
53.37M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Theratechnologies | 84.32M |
Owlet | 78.61M |
OptiNose | 75.67M |
Aadi Bioscience | 25.07M |
Singular Genomics Systems | 2.67M |
Entera Bio | 99.00K |
NTRB News
- 23 days ago - Nutriband Inc. Issued Full Patent from the Chinese National Intellectual Property Administrant for Its "Abuse and Misuse Deterrent Transdermal System" Application - Accesswire
- 5 weeks ago - Nutriband Inc Mosquito Repellent Patch Approved by Ministry of Health of Costa Rica - Accesswire
- 7 weeks ago - Join Nutriband's Exclusive Live Investor Webinar and Q&A Session on October 17 - Accesswire
- 2 months ago - Nutriband Receives China Patent Notice of Allowance for Its Aversa(TM) Abuse Deterrent Transdermal Technology - Accesswire
- 2 months ago - Nutriband Licenses Bitrex(R) Brand Aversive Agent for Its Lead Product - Aversa(TM) Fentanyl Transdermal Patch - Accesswire
- 2 months ago - Nutriband Inc. Authorizes $1M Share Buyback Program - Accesswire
- 2 months ago - Nutriband Inc. Quarterly Report Highlights Strong Cash Position, and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025 - Accesswire
- 4 months ago - Join Nutriband's Exclusive Live Investor Webinar and Q&A Session on July 25 - Accesswire